Key Considerations To Optimize Performance And Mitigate Risk In Plasmid DNA Manufacturing

Plasmid DNA is a critical starting material that forms the foundation for many therapeutic strategies. Fueled by increases in development of cell and gene therapies as well as the rapid emergence of mRNA technology, the plasmid DNA manufacturing market is expected to see over 20% growth by 2030 according to recent industry reports.*

There are many considerations when establishing your plasmid DNA manufacturing strategy from a technical, quality, and regulatory perspective, many of which can be addressed by leveraging a knowledgeable CDMO partner. View the on-demand webinar for an in-depth overview of common challenges facing advanced therapy developers using pDNA, as well as strategies to mitigate risk and achieve both cost and quality goals in plasmid manufacturing. Specific topics include:

• Plasmid design components to maximize downstream performance
• Understanding of evolving regulatory landscape and documentation requirements for filing
• Guidance on application of GMP principles and plasmid quality based on phase of development
• Questions to ask your plasmid manufacturing partner to accurately gauge product quality
• Benefits of an integrated CDMO service provider to streamline plasmid production and ensure a reliable supply

*Source: https://www.cellandgene.com/doc/plasmid-dna-manufacturing-to-see-impressive-growth-in-years-ahead-0001